Dr. Dave Smoller, CSO, Sigma Life Science Bio and Contact Info
Dr. Supriya Shivakumar, Global Marketing Manager, Sigma Life Science Bio and Contact Info
Listen (9:42) ZFN technology and products
Listen (2:09) "A game changer"
Listen (3:42) Rats better than mice for studying neural diseases
Listen (2:12) Improvement in products
Listen (3:00) Why buy when researchers can make their own?
Listen (6:24) Revival of gene therapy?
Listen (5:59) Recent study on hemophilia
Listen (7:35) Applications in AgBio
Listen (7:55) If we'd only had ZFNs back when . . .
(ZFNs) or Zinc finger nucleases are a class of engineered DNA-binding proteins that enable targeted editing of the genome. They do this by creating double-strand breaks in DNA at virtually any specific location. Through homologous and non-homologous recombination, the technology can generate precisely targeted genomic edits including gene deletions (Knockouts), integrations, or modifications. The technology holds great promise for treating human disease such as hemophilia and sickle cell anemia and may revive gene therapy. In addition the ZFNs are offering new possibilities in plant and animal research. Developed first by Sangamo Biosciences, the technology has been licensed to Sigma Life Science which they offer as their CompoZr ZFN technology.
Here to talk to us about this exciting technology and the promise of its many applications is Dr. Dave Smoller, CSO at Sigma and Supriya Shivakumar, global marketing manager for functional Genomics at Sigma. Dave was formerly president of the Research Biotech Business Unit at Sigma. Before that he founded two companies which were acquired, ProteoPlex, focused on functional genomics and Genome Systems, which offered access to Human Genome project related technologies. Supriya did graduate studies in Harold Varmus’ lab at UC San Francisco, where she used reverse genetics approaches to study oncogenes and their normal biological role in C. elegans.